摘要
目的分析20例胰腺癌及胰腺良性病变组织中miR-216a的表达差异,探讨miR-216a在胰腺癌中表达的临床意义及潜在应用价值。方法收集14例胰腺癌患者手术标本的癌组织,6例胰腺良性病变组织作为对照。采用Agilent人microRNA寡核苷酸基因芯片(V12.0)在基因组范围内检测20例组织标本的miR-216a表达,并分析其与胰腺癌临床病理参数的关系。结果胰腺癌组织中miR-216a的表达显著低于胰腺良性病变组织(P=0.000),miR-216a在胰腺癌组织中的表达与患者年龄、性别、吸烟、临床分期、局部淋巴结转移,远处转移、CA19-9浓度、肿瘤分化程度、神经束膜侵犯、脉管侵犯均无相关性(P>0.05),而与肿瘤T分期具有显著统计学意义(P=0.002)。结论 miR-216a在胰腺癌的发生、发展过程可能发挥重要作用,检测miR-216a有望成为胰腺癌新的肿瘤标记物或预后因子。
Objective To explore the clinical significance of miRNA-216a expression in pancreatic cancer. Methods Fourteen patients with pancreatic cancer undergoing pancreticoduedenectomy and 6 patients with benign pancreas lesions were examined for miR-216a expressions in the tumor or lesion tissues using Agilent Human miRNA Microarray （V12.0）. The relationship between miR-216a expressions and the clinicopathological features of the patients was analyzed. Results The expression of miRNA-216a was significantly lower in pancreatic cancer than in benign pancreas lesions （P=0.000）. The expression of miRNA-216a was significantly correlated with the T stage of the tumor （P=0.002）, but not with the patients＇ age, gender, smoking status, tumor stage, lymph node metastases, distant metastasis, tumor differentiation, nerve invasion, vessel invasion or serum CA19-9 level （P〉0.05）. Conclusions The down-regulated expression of miR-216a in pancreatic cancer suggests the involvement of miR-216a in the tumorigenesis and development of pancreatic cancer, miR-216a may potentially serve as a novel tumor marker and also a prognostic factor for pancreatic cancer.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2012年第11期1628-1631,共4页
Journal of Southern Medical University
基金
广东省自然科学基金(2011010005036)
卫生部卫生公益性行业科研专项(201202007)
